Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients
Topic / Pathology
- Parkinson's Disease
Objectives
To have more informations, click on the link below:
https://clinicaltrials.gov/ct2/show/record/NCT03162874?term=ambled&cond=Parkinson&draw=2&rank=1
Sponsor
Prexton Therapeutics
Scientific publication(s)
-
Rascol O et al. A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease. Mov Disord. 2022 May;37(5):1088-1093.
Status
Published results
